Create Account | Sign In: Author or Forum

Search Symptoms

Category: Endocrinology | Family Medicine | Internal Medicine | Nephrology | Nursing | Pathology | Urology | Journal

Back to Journal Articles

Targeted Therapies in Diabetic Nephropathy Examined

Last Updated: November 09, 2009.

Poly(ADP-ribose) polymerase activation appears to play a role in numerous changes associated with early kidney disease seen in type 1 diabetes, according to research published online Oct. 23 in Endocrinology.

MONDAY, Nov. 9 (HealthDay News) -- Poly(ADP-ribose) polymerase (PARP) activation appears to play a role in numerous changes associated with early kidney disease seen in type 1 diabetes, according to research published online Oct. 23 in Endocrinology.

Viktor R. Drel, Ph.D., of the Louisiana State University System in Baton Rouge, and colleagues analyzed data from rats that were maintained as controls or rendered diabetic with streptozotocin. Diabetic rats were treated with the PARP inhibitors 1,5- isoquinolinediol (ISO) or 10-(4-methyl-piperazin-1-ylmethyl)-2H-7-oxa-1,2-diaza-benzo[de]anthracen-3-one (GPI-15427) for 10 weeks, or left untreated.

In untreated diabetic rats, the researchers found that urinary albumin excretion was elevated approximately four-fold compared to nondiabetic controls, but ISO and GPI-15427 largely prevented the increase. In diabetic rats, renal concentrations of transforming growth factor-β1, vascular endothelial growth factor, tumor necrosis factor-α, lipid peroxidation products, nitrotyrosine, and monocyte chemoattractant protein-1 were all increased, but these changes were inhibited by the PARP inhibitors.

"In conclusion, PARP activation contributes to advanced glycation end product formation, oxidative-nitrosative stress, and proinflammatory response in the diabetic kidney and triggers multiple mechanisms leading to albuminuria, mesangial expansion, and podocyte loss in early type 1 diabetic nephropathy," the authors write.

Two co-authors formerly worked at MGI Pharma, which is now part of Eisai Inc., a company developing PARP inhibitors; and another co-author currently works at Eisai Inc.

Abstract
Full Text (subscription or payment may be required)


Previous: ACAAI: EMS Personnel May Not Carry Epinephrine Next: Lumbar Spine Functional Restoration Program Evaluated

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: